Your browser doesn't support javascript.
loading
Practical aspects of discovery pathology.
Burkhardt, John E; Ryan, Anne M; Germann, Paul-Georg.
Afiliação
  • Burkhardt JE; Department of Drug Safety Evaluation, Pfizer Global Research and Development, Groton, CT 06340, USA. John_E_Burkhardt@groton.pfizer.com
Toxicol Pathol ; 30(1): 8-10, 2002.
Article em En | MEDLINE | ID: mdl-11890479
ABSTRACT
Pathologists are uniquely qualified to play a central role in driving drug discovery and development programs by 1) establishing disease models to assess potential therapies, 2) characterizing modifications in the disease state in response to therapies, 3) characterizing toxicologic mechanisms and responses to drug candidates, and 4) facilitating multidisciplinary efforts to monitor for the clinical occurrence, progression, and reversibility of adverse events. Such nontraditional deployment of resources must, to be viable, produce benefits to the pharmaceutical industry comparable to those of more conventional activities such as delivery of data in nonclinical safety studies. Additionally, benefits must be tangible from standpoints such as time savings or improved quality of research decisions, manifesting as either program acceleration or improved candidate survival.
Assuntos
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Patologia Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2002 Tipo de documento: Article
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Patologia Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2002 Tipo de documento: Article